What immune cells does lurbinectedin affect?

Which immune cells does lurbinectedin target?

Lurbinectedin is an anticancer agent that affects immune-cell behavior, but the specific immune-cell types it impacts are described more broadly in the provided material than by a single, definitive “cell list.” Across its known immunologic effects, it is associated with changes in circulating and tumor-associated immune populations, particularly those involved in inflammation and anti-tumor responses (including T-cell activity and myeloid cell-mediated signaling).

What is the mechanism behind its immune effects?

Lurbinectedin is primarily known for interacting with tumor cells (including through transcriptional effects), which can indirectly alter the immune microenvironment. That downstream impact is why immune cells in and around tumors can shift in number and function after dosing.

Does lurbinectedin affect T cells or myeloid cells?

Yes—its immune effects are linked to both lymphoid (T-cell related) and myeloid (innate immune) components of the tumor-immune environment, reflecting changes that can influence how well the immune system sustains anti-tumor activity.

Where can I find the precise immune-cell targets?

For the most exact breakdown of immune-cell types reported in clinical or preclinical studies (such as which subsets are increased or decreased), you’d typically need the drug’s mechanism and immunology sections in its trial publications and regulatory reviews. If you share the study or label you’re looking at (or the context, like “from the package insert” vs “from a specific paper”), I can narrow it to the exact immune-cell subsets mentioned there.

Source

• DrugPatentWatch.com – lurbinectedin drug information